Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Harvard Business School
Mallinckrodt
Colorcon
Dow

Last Updated: January 25, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for PLX3397

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug PLX3397?

PLX3397 is an investigational drug.

There have been 21 clinical trials for PLX3397. The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2015.

The most common disease conditions in clinical trials are Melanoma, Leukemia, and Neurofibroma. The leading clinical trial sponsors are Plexxikon, National Cancer Institute (NCI), and Seoul National University Hospital.

There are fifteen US patents protecting this investigational drug and one hundred and thirty-five international patents.

Recent Clinical Trials for PLX3397
TitleSponsorPhase
Biomarker Study of PDR001 in Combination With MCS110 in Gastric CancerSeoul National University HospitalPhase 2
A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated MelanomaPlexxikonPhase 1/Phase 2
Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal CancersAstraZenecaPhase 1

See all PLX3397 clinical trials

Clinical Trial Summary for PLX3397

Top disease conditions for PLX3397
Top clinical trial sponsors for PLX3397

See all PLX3397 clinical trials

US Patents for PLX3397

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
PLX3397   Start Trial Synthesis of a compound that modulates kinases Plexxikon Inc. (Berkeley, CA) Daiichi Sankyo Company, Limited (Tokyo, JP)   Start Trial
PLX3397   Start Trial Solid forms of a compound modulating kinases Plexxikon Inc. (Berkeley, CA)   Start Trial
PLX3397   Start Trial Synthesis of a compound that modulates kinases Plexxikon Inc. (Berkeley, CA) Daiichi Sankyo Company, Limited (Tokyo, JP)   Start Trial
PLX3397   Start Trial Compounds modulating c-fms and/or c-kit activity and uses therefor Plexxikon, Inc. (Berkeley, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for PLX3397

Drugname Country Document Number Estimated Expiration Related US Patent
PLX3397 Australia 2016258027 2035-05-06   Start Trial
PLX3397 Brazil 112017023490 2035-05-06   Start Trial
PLX3397 Brazil 112017023540 2035-05-06   Start Trial
PLX3397 Canada 2984899 2035-05-06   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Dow
McKinsey
AstraZeneca
Johnson and Johnson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.